An observational study in Phenylketonuria (PKU), sponsored by BioMarin Pharmaceutical. Recruiting at 11 sites in United States. Per ClinicalTrials.gov, last updated 2026-03-24.
Sponsored by BioMarin Pharmaceutical · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 35 studies in Phenylketonurias by BioMarin Pharmaceutical — 3 open to participants now, 5 under way, 1 of them phase 3. Phenylketonurias · BioMarin Pharmaceutical.
Among the 35 studies in Phenylketonurias by BioMarin Pharmaceutical, this one is the only one that started in 2024, is one of 8 observational ones, and was the 33rd registered.
191 studies on the registry are indexed under Phenylketonurias; 40 are open to participants now.
Browse Phenylketonurias studies →3 of the 35 studies in Phenylketonurias by BioMarin Pharmaceutical are open now, in 3 countries. Recruiting first, the newest first:
BioMarin Pharmaceutical · Sites in United States
Ages 18–65
BioMarin Pharmaceutical · Sites in United States, Germany, Italy
By country, each count listing its studies:
Of the 31 Phenylketonurias studies recruiting now, 14 (45%) set no upper age limit and 17 (55%) stop at 75 or younger; 15 take children under 18; 8 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
35 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 10 · Phase 3 11 · Phase 4 3
First in 2004; this study’s year is marked. 1 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 200 is above the median of 37 across 61 observational studies indexed under Phenylketonurias.
Median enrollment 56 across the 26 interventional studies, 132 across the 8 observational. Of the 29 that completed or were terminated, 17 (59%) have results posted.
This tab as a report to print or save as PDF → With an account.
BioMarin Pharmaceutical is the lead sponsor of 112 studies on the registry; 13 are open to participants now.
Of its 19 completed or terminated interventional studies of FDA-regulated products, 12 (63%) have results posted.
1 of the studies in Phenylketonurias by BioMarin Pharmaceutical that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07477691BioMarin PharmaceuticalImmune Modulation During Palynziq® Treatment in Adults (IMPALA) | 2027-09-30 |
Add it to your calendar (.ics) → With an account.
Among the 35 studies in Phenylketonurias by BioMarin Pharmaceutical, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a 10-year multi-center, prospective, longitudinal, single arm study evaluating immunologic, inflammatory and laboratory parameters associated with long-term Palynziq treatment in subjects with phenylketonuria (PKU) in the United States (US). Subjects in the US for whom a clinical decision has been made that they will receive pegvaliase to treat their PKU within 30 days following the date of enrollment in Study 165-501 (incident-users) or who have previously started treatment with pegvaliase at the date of enrollment in Study 165-501 (prevalent-users) are eligible for participation in Study 165-503.
This is a 10-year multi-center, prospective, longitudinal, single arm study evaluating immunologic, inflammatory and laboratory parameters associated with long-term Palynziq treatment in subjects with phenylketonuria (PKU) in the United States (US). Subjects in the US for whom a clinical decision has been made that they will receive pegvaliase to treat their PKU within 30 days following the date of enrollment in Study 165-501 (incident-users) or who have previously started treatment with pegvaliase at the date of enrollment in Study 165-501 (prevalent-users) are eligible for participation in Study 165-503. Subjects participating in the 165-501 study who consent to participate in this study (165-503) will be requested to provide pre-dose blood samples for Phe, immunologic and inflammatory marker testing approximately every 3 months for the first 3 years of participation, then every 6 months for the remainder of the study. Subjects will be requested to provide additional pre-dose blood samples at the time of Study 165-501 -protocol defined safety events. Additional pre-dose samples will be drawn as per standard of care as detailed in protocol 165-501. The blood Phe, immunologic (PAL IgG, PEG IgG, PEG IgM, anti-pegvaliase IgE), and inflammatory (C3/C4, hsCRP) markers, will be sent to a central laboratory for processing. Data collected in the 165-501 study will be combined with the data collected in this study to decrease burden on sites for data entry and to avoid duplication of ADR reporting (see Criteria for Evaluation). The combined data will be reported in the Clinical Study Report for this study. Subjects can withdraw from Study 165-503 and remain on Study 165-501, but they cannot withdraw from Study 165-501 and remain on Study 165-503 as safety events and other data-points are collected in Study 165-501.
Subjects enrolled at US sites participating in the 165-501 study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Must be enrolled in the 165-501 PALace study. Subjects currently receiving or who plan to receive pegvaliase treatment within 30 days after the date of enrollment in the 165-501 study, including subjects who previously received pegvaliase as part of the clinical development program and have completed study participation
To evaluate immunologic and inflammatory responses associated with occurrences of
* Acute systemic hypersensitivity reaction * Anaphylaxis * Angioedema * Serum sickness * Severe hypersensitivity reaction * Severe or Persistent arthralgia * Severe injection site reaction
Time frame: A maximum of 10 years treatment duration.
Evaluation of immunologic and/or inflammatory responses over time
To evaluate immunologic and inflammatory responses (immunologic testing, inflammatory markers) associated with occurrences of end-organ function (eg, kidney, liver) related, immune-mediated adverse drug reactions (ADRs)\*
Time frame: A maximum of 10 years treatment duration.
Evaluation of immunologic responses over time
To evaluate the potential association between immunologic responses and blood Phe levels \* A list of end-organ function related, immune-mediated ADRs is included as an appendix to the statistical analysis plan (SAP).
Time frame: A maximum of 10 years treatment duration.
Started Jan 2024 (actual). Primary completion is estimated for Nov 2033, 117 months after the start.
Of 22 observational studies under Phenylketonurias, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 95. This study's planned 117 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.